allopurinol / Generic mfg. - LARVOL DELTA

Non-Cirrhotic Hyperammonemic Encephalopathy in a Critically Ill Patient (ACG 2026) - "Case Description/ A 36-year-old female with a history of gastric bypass who presented with leg ulcers and oral mucosal lesions was found to have TEN likely from allopurinol use for gout...Data points indicate concurrent interventions: no intervention (gray X), lactulose alone (blue circles), continuous renal replacement therapy (CRRT, red squares), and L-carnitine with CRRT (purple triangles)...Ammonia levels declined to within normal range (10â28 µmol/L, green shaded area) by day 29 following CRRT discontinuation. Error bars represent same-day repeated measurements."

Clinical • Autoimmune Hepatitis • Cardiovascular • CNS Disorders • Fibrosis • Gout • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Portal Hypertension • Renal Disease • Septic Shock • Steven-Johnson Syndrome

Proton Pump Inhibitors and H2-Receptor Blockers as Culprit Agents in Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Systematic Review of Case Reports (ACG 2026) - "While antibiotics, anticonvulsants, and allopurinol are well-established culprits, proton pump inhibitors (PPIs) and H2-receptor blockers (H2RBs), among the most widely prescribed drug classes globally, are underrecognized triggers...PPIs were implicated in 62% of cases; lansoprazole, omeprazole, and pantoprazole were most frequent. H2RBs accounted for 38%, with ranitidine and cimetidine most common... Twenty studies met inclusion criteria, including one two-patient case series, yielding 21 cases (10 TEN, 11 SJS). Median age was 50 years; 62% were female. Median latency to onset was 10 days."

Case report • Clinical • Review • Acute Respiratory Distress Syndrome • Cardiovascular • Infectious Disease • Renal Disease • Respiratory Diseases • Septic Shock • Steven-Johnson Syndrome

A Rash Decision: Diagnostic and Therapeutic Management of DRESS With DILI (ACG 2026) - "Case Description/ A 66 year old female with CKD3 presented with progressive fatigue and pruritic urticarial rash spreading from feet to the back after two weeks after starting colchicine and allopurinol for gout. Figure: Punch Biopsy of rash on patient's right leg, H&E 100x. Hyperkeratotic acanthotic epidermis with rare keratinocyte necrosis (arrows), papillary dermal edema, and perivascular to lichenoid superficial dermal inflammatory infiltrate of neutrophils with karyorrhexis, lymphocytes, and rare eosinophils Figure: Zone 3 hepatocyte necrosis with repair and mild associated inflammation"

Cardiovascular • Eosinophilia • Gout • Heart Failure • Hepatology • Immunology • Inflammatory Arthritis • Liver Failure • Nephrology • Renal Disease • Urticaria

Beyond Adenocarcinoma: The Diagnostic Challenge of an Atypical Pancreatic Mass Unmasking Systemic B-Cell Lymphoblastic Leukemia (ACG 2026) - "He was treated for a presumed leukemoid reaction with hydroxyurea/allopurinol, yielding hematologic improvement before discharge...The patient was started on Hyper-CVAD, dasatinib, and intrathecal chemotherapy...Figure: EUS of pancreatic lesion with FNB needle in view. Figure: MRI post-contrast image slice revealing exophytic mass in pancreas body."

IO biomarker • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • CNS Disorders • Hematological Malignancies • Hepatology • High-grade B-cell lymphoma • Leukemia • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • BCL2 • CA 19-9 • CD20 • MME • PAX5 • PTPRC

Breaking Bad: Spontaneous Tumor Lysis Syndrome in Hepatic Adenocarcinoma, an Uncommon Complication of a Rare Malignancy (ACG 2026) - "Nephrology was consulted, and treatment with rasburicase, allopurinol, and bicarbonate infusion was initiated. Figure: Table 1. Cairo-Bishop Criteria for TLS"

Acute Coronary Syndrome • Biliary Cancer • Cholangiocarcinoma • Endocrine Disorders • Hematological Malignancies • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Metabolic Disorders • Movement Disorders • Nephrology • Oncology • Renal Disease • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder • Solid Tumor • CK19 • KRT19

Study on renal protective effect of serum urate lowering therapy (clinicaltrials.gov) - P=N/A | N=90 | Recruiting | Sponsor: Tokushukai Medical Corporation Shonan Kamakura General Hospital (Clinical Research Center) | N=150 ➔ 90

Enrollment change • FGF23

Tirzepatide-Associated Drug-Induced Liver Injury in a Liver Transplant Recipient: A Case Report (ACG 2026) - "She has been on 5 mg of extended-release tacrolimus (envarsus) daily with stable therapeutic trough levels. Review of other medications was notable for allopurinol, escitalopram, and glipizide, which were long-term with stable dose...Figure: Table 1. Liver Enzyme Trends During Tirzepatide Exposure and Following Discontinuation"

Case report • Clinical • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Transplantation • Type 2 Diabetes Mellitus

Association between serum uric acid and kidney disease with pediatric focus. (PubMed, Child Kidney Dis) - "Two recent large well-designed studies failed to show that allopurinol, a uric acid-lowering agent, slows the decline in glomerular filtration rate. Nevertheless, this conclusion remains premature. The role of uric acid-lowering agents in delaying disease progression in patients with early-stage CKD, such as pediatric patients, requires further study."

Journal • Review • Chronic Kidney Disease • Nephrology • Pediatrics • Renal Disease

Beyond histocompatibility: human leukocyte antigen as a cross-disciplinary platform for immune recognition and clinical decision-making. (PubMed, Front Immunol) - "Pharmacogenomic testing has clearer clinical value for selected drugs, including abacavir, carbamazepine and allopurinol. Clinical implementation requires reliable assays, validated clinical associations, evidence of patient benefit, multi-ancestry validation, consistent reporting and equitable access. We distinguish established clinical practice from developing risk-stratification methods and early mechanistic findings."

Journal • Review • Acute Lung Injury • Bone Marrow Transplantation • Diabetes • Graft versus Host Disease • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Metabolic Disorders • Oncology • Respiratory Diseases • Solid Organ Transplantation • Systemic Lupus Erythematosus • Transplantation • Type 1 Diabetes Mellitus • HLA-E

Changes in HLA-B*58:01 Testing and SCAR Disparities Before and After the 2020 ACR Allopurinol Guidelines (ACR Convergence 2026) - No abstract available

HLA-B

Differences in Patient Characteristics and Health-Related Quality of Life Between Controlled and Uncontrolled Gout (ACR Convergence 2026) - "Significant differences were observed between controlled and uncontrolled groups in urate-lowering therapy use (allopurinol: 69% vs 49.9%, P=0.03; febuxostat: 1.5% vs 7.1%, P=0.01), health insurance coverage (P=0.005), race (P=0.01), and depression (P=0.01). Uncontrolled gout was associated with lower socio-economic status and significantly lower HRQoL, highlighting the need for improved disease management strategies and addressing the humanistic burden in this population.Copyright acknowledgemen"

Clinical • HEOR • CNS Disorders • Depression • Gout • Inflammatory Arthritis • Rheumatology

Sustained Improvement in HLA-B*5801 Testing Rates Prior to Allopurinol Initiation in High-Risk Patient Populations After an Order Menu Revision (ACR Convergence 2026) - No abstract available

Clinical • HLA-B

Efficacy and Safety of Darbinurad Combined with Allopurinol in Patients with Gout: A Randomized, Open-Label, Multiple-Dose Phase II Study (ACR Convergence 2026) - No abstract available

Clinical • P2 data • Gout • Inflammatory Arthritis • Rheumatology

Differences in the Risk of Allopurinol Hypersensitivity Syndrome Among Subgroups Defined by Self-Reported Race: An Analysis of Real-World Data in U.S. Patients with Gout (ACR Convergence 2026) - "These results demonstrate that among a real-world gout population, the risk of AHS is more than 2.3-fold higher in patients reporting Black race compared to their White counterparts, with a risk that approximates that of Asian patients. Notably, this risk appears to be independent of other known AHS risk factors. Recognizing the need for additional studies examining its implementation and uptake in real-world practice, these findings support the conditional recommendation for HLA-B*5801 screening prior to allopurinol use in both African American and Southeast Asian patient populations."

Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Gout • Heart Failure • Immunology • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • HLA-B

Reevaluating Febuxostat's Cardiovascular Black Box Warning: Comparative Safety Versus Allopurinol in a Large U.S. Gout Cohort. (ACR Convergence 2026) - No abstract available

Clinical • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial (ASH 2022) - "Background Venetoclax (VEN) plus azacitidine has an established role in the management of older patients (pts) with AML (DiNardo, NEJM 2020)...We now present an updated analysis of this trial (with >3 years median follow-up), reporting on the optimal dose of VEN with chemotherapy, with and without posaconazole (POSA), the deliverability of consolidation therapy, characteristics of treatment failure and observation of substantial treatment-free remission in subsets of pts using this time-limited, short-course regimen...For induction, VEN was administered over 14 days, commencing with a 7-day pre-chemo dose ramp-up, followed by a 7-day overlap with 5+2 chemotherapy (cytarabine 100mg/m2/d IVI d1-5 and idarubicin 12mg/m2 IV d2-3)...Induction with VEN-POSA (n=18) was also well tolerated (30-day mortality 0%) with 3 DLTs observed: 2 hematologic (1 in each cohort) and 1 due to pulmonary infiltrates occurring on d2 induction (suspected to be allopurinol..."

Clinical • Acute Myelogenous Leukemia • Hematological Disorders • Immunology • FLT3 • IDH2 • KIT • NPM1

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation (ASH 2023) - P2 | "For pts who remained high TLS risk at the time of V initiation, TLS ppx throughout dose escalation included allopurinol to start at least 3 days prior to V initiation, sevelamer to start 12 hours prior to V initiation, and oral intake of ≥2 L water daily. On days of dose escalation, ppx additionally included kayexalate, rasburicase, and IV normal saline on D1 and D2 of each dose escalation... A single cycle of O effectively reduced TLS risk prior to introduction of V escalation with most pts achieving low or med TLS risk by C1D22. Notably, 90% of pts with high pre-tx TLS risk converted to low or med risk following C1 of O allowing for outpatient V escalation per FDA label. Further, we demonstrate that V dose escalation can be safely accomplished in the outpatient setting with close monitoring regardless of TLS risk."

Clinical • Minimal residual disease • P2 data • Residual disease • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience (ASH 2025) - "Background : Venetoclax (VEN)+obinutuzumab (VO) is an effective therapy for CLL/SLL requiring regularmonitoring for tumor lysis syndrome (TLS) during VEN ramp-up...Adult pts with CLL/SLL were eligible if they: (1) startedVO per-label outside of a clinical trial in 1L, or immediately after exposure in 1L to agents with differentmechanisms of action (i.e., BTKi, anti-CD20 only) of <30 days; (2) prior to VEN start, had either (i) lowphysician-determined tumor burden (TB) (i.e., all lymph nodes [LN] <5 cm and ALC <25 x 109/L), or (ii)medium physician-determined TB (i.e., any LN ≥5-<10 cm or ALC ≥25 x 109/L) with creatinine clearance≥80 mL/min; (3) had no strong CYP3A inhibitors or prophylactic rasburicase from 3 days prior to VENstart until end of VEN ramp-up; and (4) had VEN ramp-up in an outpatient setting.TB-related labs/imaging was assessed from 2 months prior to obinutuzumab initiation (i.e., index date)until VEN start...Prior to VEN ramp-up, all pts..."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Diabetes • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • IGH • TP53

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma (ASH 2024) - P2 | "However, PFS was inferior for patients (pts) treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 days) compared with other regimens, supporting intensification of therapy beyond R-CHOP-21 in this entity. (eg. Allopurinol, co-trimoxazole). Study enrolment, safety and efficacy analyses are ongoing."

Clinical • P2 data • Alopecia • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • PD-L2

A Microneedle Platform Co-loaded with Eugenol, Chlorogenic Acid, and Allopurinol for In Vivo Modulation of Pathological Crystal Formation in Experimental Gouty Arthritis. (PubMed, ACS Appl Mater Interfaces) - "Synovial IL-1β, IL-6, and TNF-α positive areas were all below 5% in the MN-treated group and were significantly lower than those in untreated rats (n = 3, all P < 0.0001), accompanied by improved synovial tissue integrity. This study provides in vivo experimental evidence that pathological MSU crystallization can be locally modulated through an interfacial-engineered MN platform, offering a new strategy for gout therapy by integrating crystal regulation, anti-inflammatory intervention, and urate-lowering treatment."

Journal • Preclinical • Gout • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology • IL1B • IL6 • TNFA

When Two High-Risk Drugs Collide: Allopurinol-Induced DRESS Syndrome Exacerbated by Cotrimoxazole (EADV 2026) - No abstract available

Allopurinol-induced DRESS syndrome: a clinical entry point towards the diagnosis of hereditary hemochromatosis (EADV 2026) - No abstract available

Clinical • Genetic Disorders • Hematological Disorders • Hepatology

Effective Use of 3% Topical Allopurinol in Intractable Granulomatous Tattoo Reaction: Case Report and Review (EADV 2026) - No abstract available

Case report • Clinical • Review

Allopurinol-Induced DRESS Syndrome A Clinical Gateway to Diagnosing Hereditary Hemochromatosis (EADV 2026) - No abstract available

Clinical • Genetic Disorders • Hematological Disorders • Hepatology

In vitro, in vivo, and computational evaluation of xanthine oxidase inhibitory and antihyperuricemic activities of Piper betle L. ethyl acetate fraction. (PubMed, J Complement Integr Med) - "The ethyl acetate fraction of P. betle demonstrated preclinical xanthine oxidase inhibitory, urate-lowering, and anti-inflammatory potential. Stronger chemical standardization and mechanistic validation are required before therapeutic relevance can be inferred."

Journal • Preclinical • Gout • Inflammatory Arthritis • Metabolic Disorders • Pain • Rheumatology